Expansion Opportunities Ceribell is expanding product capabilities with a Delirium monitoring solution, a next-generation hardware platform planned for 2027, and an upcoming recorder with camera and EKG integration. This signals opportunities to cross-sell enhanced EEG monitoring, delirium assessment, and integrated patient monitoring packages to acute care facilities seeking comprehensive neurological care tools.

Strategic Partnerships Recent board additions and continued FDA clearances suggest a strategic push to scale adoption in hospitals and health systems. Use these moments to engage C-suite and procurement by aligning Ceribell’s AI-driven EEG platform with hospital goals for faster diagnosis, reduced ICU stays, and improved patient outcomes.

Revenue Growth With reported revenue in the tens of millions and a healthy funding runway, Ceribell presents a momentum opportunity for bundled solutions in emergency rooms and ICUs. Target high-volume centers and IDNs aiming to standardize acute care EEG workflows and reduce time to seizure diagnosis.

Technology Enablement The Ceribell System combines portable hardware with AI-powered algorithms and Artifact Reduction technology. Leverage this to position value propositions around faster diagnosis, continuous monitoring, and operational efficiency to reduce clinician time per patient and improve bed turnover.

Market Readiness FDA 510(k) clearance for suspected seizure activity and a clear focus on acute care settings indicate readiness for rapid deployment in hospitals, EDs, and ICUs. Approach purchasing teams with deployment playbooks, clinical evidence, and training programs to shorten time-to-value for new sites.